BIT doesn't have the time (or money) for another phase 2 trial, but yes I think your assessment is correct on what is needed. Without evidence in humans of a direct effect on HIV at a dose the patients can handle they are not going to able to move into a phase 3 trial.
On top of this they need long term side effect data and data on how quickly the virus develops resistance to BIT225.
I wouldn't be too worried about Abixav though - their HIV drug is going nowhere either.
BIT doesn't have the time (or money) for another phase 2 trial,...
-
- There are more pages in this discussion • 11,977 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
